

Innoventric's *Trillium™* Technology

- **General**

Innoventric is a medical device company, founded in 2017. The company is about to complete its European FIH clinical trial with almost 20 patients implanted so far. The company runs a lean and highly focused operation with an experienced, hands-on management team.

- **The Need**

In Tricuspid Regurgitation (TR) the tricuspid valve does not close properly. TR causes blood reflux into the atrium during systole, which results in a decreased cardiac output and increased venous pressure.

TR leads to: internal organ congestion, peripheral edema, and if untreated, it eventually leads to heart failure and death.

Available treatments for TR are open heart surgery or medication. However, open heart surgery is rarely carried out, mainly because of its high mortality rates. Medication, on the other hand, does not solve the problem and allows the disease to progress.

- **The Solution**

The Trillium™ is a novel percutaneous tricuspid valve replacement, specifically designed for the tricuspid valve environment. The Trillium™ is a cross-caval stent graft with a valved wall that spans the right atrium. The percutaneous implantation of the Trillium™ replaces open heart surgery and offers a full treatment for TR, while leaving the native valve untouched.

The procedure is very simple, takes only a few minutes and does not require echo guidance, the use of a heart-lung pump or rapid pacing of the heart.

- **Market (US & EU)**

Total number of patients with moderate-severe TR: **4M**

Annual number of patients with moderate-severe TR: **500K**

Potential market: **8-10B\$, annually**

- **Other**

Innoventric holds 4 patents, with its main patent already approved in the US, EU, China and Australia.

Innoventric has additional technologies for the treatment of TR under development. Two products are already under clinical investigation.

Innoventric has been acknowledged by the Israeli Innovation Authority for four consecutive years.

Innoventric won the prestigious Horizon Europe EISME grant (€2.5M), placing the company among the top 1% out of 4,500 European technology companies which applied.